Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Tg therapeutics, inc. crawled time : 12:00 save search
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
briumvi neurology sclerosis for meeting therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -3.94%
H: 3.0%
C: -0.57%
briumvi neurology presentation sclerosis for meeting therapeutics
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 16.32%
H: 16.75%
C: 8.96%
business update therapeutics financial results
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 1.35%
H: 1.67%
C: -1.04%
briumvi therapeutics
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Published: 2024-01-10 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 7.33%
H: 0.53%
C: -21.2%
year revenue therapeutics
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.985 -6.86% 93K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy
TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
Published: 2023-11-03 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 4.42%
H: 6.35%
C: 1.75%
conference immunology therapeutics
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-01 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 31.82%
H: 12.27%
C: -0.69%
business update therapeutics financial results
TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
Published: 2023-10-30 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 0.57%
H: 13.43%
C: 5.57%
conference business update therapeutics financial results
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Published: 2023-10-02 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: -3.43%
briumvi sclerosis treatment research meeting therapeutics
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Published: 2023-09-22 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 0.22%
H: 2.59%
C: -1.4%
conference global therapeutics
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-07 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -1.18%
H: 4.4%
C: 3.39%
conference global therapeutics
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
conference business update therapeutics financial results
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -1.32%
H: 4.2%
C: -1.37%
conference therapeutics
TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Published: 2023-03-31 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 2.46%
H: 2.0%
C: 0.33%
chmp positive sclerosis treatment therapeutics
TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published: 2022-10-26 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -0.93%
H: 11.07%
C: 3.75%
treatment trials research therapeutics presentation sclerosis multiple sclerosis
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and Research in Multiple Sclerosis
Published: 2022-10-13 (Crawled : 12:00) - biospace.com/
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: -5.1%
H: 7.04%
C: 5.93%
treatment trials research therapeutics sclerosis multiple sclerosis
TG Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Published: 2022-09-09 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 0.86%
H: 3.5%
C: 2.85%
global conference therapeutics
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Published: 2022-08-25 (Crawled : 12:00) - globenewswire.com
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 1.34%
H: 2.77%
C: 0.66%
trials therapeutics results
TG Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsConference call to be held today, August 8, 2022 at 8:30 AM ET
Published: 2022-08-08 (Crawled : 12:00) - biospace.com/
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 4.01%
H: 16.67%
C: 16.05%
therapeutics update
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.